Advertisements



CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat. .....»»

Category: personnelSource: nytJun 12th, 2019

CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors

Shares of CymaBay Therapeutics Inc. plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did n.....»»

Category: topSource: marketwatchJun 11th, 2019

CymaBay reports topline 12-week data from ongoing Phase 2b study of seladelpar

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 11th, 2019

Athenex Rallies on Positive Early Data on Psoriasis Candidate

Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for .....»»

Category: worldSource: nytJun 10th, 2019

Amgen"s early-stage study of cancer treatment had "adverse events" in nearly half of its patients

Amgen Inc. said Wednesday data from phase 1 studies of an investigational bispecific T cell engager (BiTE) molecules, updated with investigational AMG 420 results for the treatment .....»»

Category: topSource: marketwatchJun 5th, 2019

Meet One of ASCO’s First Losers

Turning Point Therapeutics shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients......»»

Category: blogSource: 247wallstMay 31st, 2019

Biogen announces new interim data from EVOLVE-MS-1 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 30th, 2019

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus......»»

Category: blogSource: 247wallstMay 29th, 2019

OncoSec reports interim data from Keynote-890 study of breast cancer combination

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 22nd, 2019

Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update

Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in.....»»

Category: earningsSource: benzingaMay 15th, 2019

Gilead shares slip 0.2% after second NASH trial fails

Shares of Gilead Sciences Inc. slipped 0.2% in premarket trade Thursday after the company said a late-stage study lo.....»»

Category: topSource: marketwatchApr 25th, 2019

Emergent"s (EBS) Chikungunya Vaccine Positive in Phase II Study

Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate .....»»

Category: dealsSource: nytApr 17th, 2019

Wave Life Sciences Plunges After DMD Study Data Readout

Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage developm.....»»

Category: dealsSource: nytApr 17th, 2019

Intercept falls after releasing "supportive data" from Phase 3 NASH study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: smallbizSource: nytApr 11th, 2019

Madrigal Pharmaceuticals to present additional data from Phase 2 NASH study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2019

What’s Next for Sangamo After This Hemophilia Study

Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer......»»

Category: blogSource: 247wallstApr 2nd, 2019

Sangamo, Pfizer announces interim data from Phase 1/2 Alta study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019

Rhythm Pharmaceuticals announces interim data from Phase 2 setmelanotid study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 28th, 2019

Dynavax reports interim data for study of SD-101 in combination Merck"s Keytruda

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Gilead (GILD) Presents Encouraging Data on NASH Therapies

Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris. Gilead Sciences, Inc. GILD announced encouraging data from .....»»

Category: smallbizSource: nytApr 16th, 2018

Gilead presents data from proof-of-concept study in NASH patients

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 13th, 2018